COMPASS Pathways presents largest ever study of psilocybin therapy, at American Psychiatric Association annual meeting May 23, 2022
MindMed Collaborators Prof. Liechti and Dr. Holze Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in… May 11, 2022
COMP360 Psilocybin Therapy Shows Potential In Exploratory Open-Label Studies For Anorexia Nervosa And Severe… May 3, 2022
Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and… Apr 13, 2022
